CINRYZE

Phase 3Small molecule

Takeda

CINRYZE is one of 59 small molecule programs targeting Kidney Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Hereditary AngioedemaActive, not recruiting

Kidney TransplantPhase 3

Active, not recruiting

Hereditary AngioedemaPhase 2

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Simulect

Novartis

Preclinical

15 3

Medrol

Pfizer

Preclinical

12 4

CINRYZE

Takeda

Phase 3

1 5

Zinbryta

Roche

Preclinical

6 6

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 7

Cysteine Hydrochloride

Novartis

Preclinical

1 8

Radicava

Shionogi

Preclinical

1 9

Sensipar

Amgen

Preclinical

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%

Unknown status·UUniversity of Wisconsin, Madison·Phase 1·NCT02435732·72 enrolled

Hereditary Angioedema1 trial

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Completed· Takeda logo

Takeda·Phase 2·NCT01095510·9 enrolled

Kidney Transplant1 trial

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

Terminated· Takeda logo

Takeda·Phase 3·NCT02547220·39 enrolled

Tics1 trial

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

Completed· Takeda logo

Takeda·Phase 2·NCT01095497·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CINRYZE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CINRYZE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CINRYZE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

CINRYZE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Hereditary Angioedema1 trial

Kidney Transplant1 trial

Tics1 trial

References

Drug Info

Quick Facts

Related News